Abemaciclib treatment patterns and outcome in HR+/HER2- locally advanced or metastatic breast cancer: a real-world study from Kuwait and Lebanon
The present real-world evidence confirms the feasibility and effectiveness, in terms of response rate and PFS, of abemaciclib in patients with HR+/HER2- patients with locally advanced or mBC from Kuwait and Lebanon in the Middle East region.
Authors
- Soniya Rai
- Hady Ghanem (ORCID: https://orcid.org/0000-0002-3575-2187)
- A. Rosca
- A.M.E. Nouri (ORCID: https://orcid.org/0000-0001-6005-1414)
- M. Ziad Saghir (ORCID: https://orcid.org/0000-0002-6199-0314)
- Joseph Kattan
- Johannes H. Dreyer
- Faisal Al Terkait
- Cynthia Bishouti
Institutions
- University Medical Center Rizk Hospital (LB)
- Kuwait Cancer Control Center (KW)
- American University of Beirut Medical Center (LB)
- Hôtel-Dieu de France (LB)
- Dubai Medical College (AE)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-06-17
- DOI
- https://doi.org/10.3389/fonc.2025.1437380
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company